Boston Scientific Announces Schedule for Cardiostim World Congress
NATICK, Mass., June 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's key events and sponsored research at the 17th Cardiostim World Congress, June 16 – 19 in Nice, France.
(All times are local; all events take place in the Nice Acropolis Convention Center unless otherwise indicated.)
Sessions related to Boston Scientific's landmark MADIT-CRT heart failure trial:
MADIT-CRT is the world's largest randomized study of New York Heart Association (NYHA) Class I and II patients(1), with more than 1,800 patients enrolled at 110 centers worldwide. Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine. Boston Scientific currently has an application under review with the U.S. Food and Drug Administration (FDA) for the expansion of its CRT-D indication to include high-risk(2) NYHA Class I and II patients with Left Bundle Branch Block.
- Results of MADIT-CRT Trial: Data on QRS Duration, Gender and Echo. Arthur Moss, M.D., Principal Investigator of the MADIT-CRT trial, will present results on June 16, 9:00 – 9:30 a.m. during Session 12 in Room 3.2.
- CRT-D Effectiveness by QRS Duration and Morphology in MADIT-CRT Patients. Dr. Moss will present results on June 16, 2:45 - 3:00 p.m. during Session 46 in Room 1.2.
- MADIT-CRT: Who are the Super Responders to Cardiac Resynchronization Therapy? Dr. Moss will present results on June 16, 5:00 - 5:15 p.m. during Session 64 in Room 2.6.
- Boston Scientific Symposium: From Mirowski to MADIT-CRT: 30 years - Is Today's Technology Fulfilling Needs of Indicated Patients? Dr. Moss and Philippe Mabo, M.D., will chair a discussion on device therapy, clinical trials and physician practice on June 17, 11:00 a.m. - 12:30 p.m. during Session 112 in Room 3.2.
- Predictors of Outcome to Preventive Cardiac Resynchronization Therapy in MADIT-CRT. Dr. Moss will present results on June 18, 2:00 - 2:15 p.m. during Session 205 in Room 1.1.
- MADIT-CRT: Cardiac Resynchronization Therapy Reduces All-Cause Mortality in Females. Results will be featured on June 18, 2:00 - 5:30 p.m. during Session 216/P in the Poster Area on Level 3.
Sessions related to Boston Scientific's ALTITUDE clinical science program:
The ALTITUDE clinical science program analyzes comprehensive data from the Company's LATITUDE® Patient Management system. The ALTITUDE program enhances understanding of device therapy, outcomes and disease progression. The LATITUDE system allows physicians to conduct remote follow-up of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled visits and send data directly to physicians.
- Tachycardia Detection Programming and Shock Incidence in the ALTITUDE Study. F. Roosevelt Gilliam, M.D., will present results on June 17, 10:15 - 10:30 a.m. during Session 86 in Room 1.2.
- Noise and Oversensing-Related Inappropriate ICD Shocks Diagnosed with Remote Monitoring: The ALTITUDE EGM Study. Samuel Asirvatham, M.D., will present results on June 17, 10:00 - 10:15 a.m. during Session 86 in Room 1.2.
Other activities and sessions of interest:
- Boston Scientific Symposium: Applications and Uses of Different Ablation Catheter Tips. Serge Boveda, M.D., and Jose Guerra, M.D., will chair a discussion on ablation clinical experience on June 16, 2:00 - 3:30 p.m. during Session 47 in Room 1.3.
- The Jacques Mugica Conference. Kenneth Stein, M.D., Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group will co-chair the Jacques Mugica Conference on June 18, 4:00 - 5:30 p.m. during Session 235 in Room 3.5. Dr. Stein is also a featured speaker during this session and will deliver a presentation titled "A Multi-Sensor Approach to the Early Identification of Heart Failure Decompensation: Building a Better Mousetrap."
Boston Scientific will present its latest cardiac rhythm management and electrophysiology products at booths #D16 and D8.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth strategies. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
(1) The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden. MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).
(2) High-risk is defined as QRS width greater than or equal to 130 milliseconds with Left Ventricular Ejection Fraction less than or equal to 30% and Left Bundle Branch Block (LBBB). LBBB is a condition in which the activation of the left ventricle is delayed. As a result, portions of the left ventricle contract later than the rest of the left ventricle and right ventricle, reducing the heart's pumping ability.